Safety, tolerability, pharmacokinetics and preliminary antitumour activity of an antisense oligonucleotide targeting STAT3 (danvatirsen) as monotherapy and in combination with durvalumab in Japanese patients with advanced solid malignancies: a phase 1 study

Safety, tolerability, pharmacokinetics and preliminary antitumour activity of an antisense oligonucleotide targeting STAT3 (danvatirsen) as monotherapy and in combination with durvalumab in Japanese patients with advanced solid malignancies: a phase 1 study

Objectives We assessed the safety, tolerability, pharmacokinetics, preliminary antitumour activity and pharmacodynamics of danvatirsen, an antisense oligonucleotide targeting signal transducer and activator of transcription 3 (STAT3), monotherapy and danvatirsen plus durvalumab, an antiprogrammed ce...

Full description

Bibliographic Details
Main Authors: Yasutoshi Kuboki, Tomohiro Nishina, Tomoko Fujita, Naoto Yoshizuka, Ko Sugibayashi, Kosho Murayama
Format: Article
Language:English
Published: BMJ Publishing Group 2022-10-01
Series:BMJ Open
Online Access:https://bmjopen.bmj.com/content/12/10/e055718.full

Internet

https://bmjopen.bmj.com/content/12/10/e055718.full

Similar Items